Analysts Have Conflicting Sentiments on These Healthcare Companies: Agile Therapeutics (AGRX), Check-Cap (CHEK) and Doximity (DOCS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Agile Therapeutics (AGRX – Research Report), Check-Cap (CHEK – Research Report) and Doximity (DOCS – Research Report).

Agile Therapeutics (AGRX)

In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Agile Therapeutics, with a price target of $12.00. The company’s shares closed last Tuesday at $3.64, close to its 52-week low of $3.36.

According to TipRanks.com, Livnat is a 2-star analyst with an average return of 0.0% and a 41.2% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Satsuma Pharmaceuticals, and Tarsus Pharmaceuticals.

Currently, the analyst consensus on Agile Therapeutics is a Moderate Buy with an average price target of $12.00.

See Insiders’ Hot Stocks on TipRanks >>

Check-Cap (CHEK)

H.C. Wainwright analyst Yi Chen downgraded Check-Cap to Hold today. The company’s shares closed last Tuesday at $1.95, close to its 52-week low of $1.22.

According to TipRanks.com, Chen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -30.1% and a 25.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, HTG Molecular Diagnostics, and EyePoint Pharmaceuticals.

The the analyst consensus on Check-Cap is currently a Hold rating.

Doximity (DOCS)

BTIG analyst David Larsen maintained a Hold rating on Doximity today. The company’s shares closed last Tuesday at $34.06.

According to TipRanks.com, Larsen has 0 stars on 0-5 stars ranking scale with an average return of -10.2% and a 33.2% success rate. Larsen covers the Healthcare sector, focusing on stocks such as Privia Health Group, Oak Street Health, and Simulations Plus.

Currently, the analyst consensus on Doximity is a Hold with an average price target of $36.33, representing a 8.0% upside. In a report issued on June 5, Truist Financial also maintained a Hold rating on the stock with a $33.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AGRX:

• Agile Therapeutics Announces Closing of $7.5 Million Public Offering
• Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
• Agile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023
• AGRX Earnings this Week: How Will it Perform?
• Agile Therapeutics sees Q1 revenue $3.8M-$4.0M